Maillard reactions in pharmaceutical formulations and human health

International Journal of Pharmaceutical Compounding

Volumn 15, Issue 1, 2011, Pages 32-40

  Newton, David W ^a  

^a SHENANDOAH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; AMPHETAMINE; AMPICILLIN; DAPTOMYCIN; FLUOXETINE; GLUCOSE; HEMOGLOBIN A1C; LACTOSE; OSELTAMIVIR; PARENTERAL SOLUTION; PROCAINAMIDE; SUGAR; SULFAMETHOXAZOLE;

CATALYSIS; DRUG DEGRADATION; DRUG FORMULATION; GLYCATION; HEALTH; HEALTH HAZARD; HUMAN; PARENTERAL NUTRITION; REVIEW; TEMPERATURE;

EID: 79251481134     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Maillard LC. Action des acides amines sur les sucres: Formation des melanoidines par voie méthodique. Compte Rendu Acad Sci 1912; 154: 66-68.
2. Baynes JW, Monnier VM, Ames JM et al, eds. The Maillard reaction: Chemistry at the interface of nutrition, aging, and disease. Ann NY Acad Sci 2005; 1043: xix-xx.
3. Finot P-A. Historical perspective of the Maillard reaction in food science. In: Baynes JW, Monnier VM, Ames JM et al, eds. The Maillard reaction: Chemistry at the interface of nutrition, aging, and disease. Ann NY Acad Sci 2005; 1043: 1-8.
4. O'Neil MJ, ed. The Merck Index. 14th ed. Whitehouse Station, NJ: Merck & Co.; 2006: ONR-3, ONR-57.
5. Wirth DD, Baertschi SW, Johnson RA et al. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci 1998; 87(1): 31-39.
6. Labuza TP, Baisier WM, eds. Maillard Reaction in Chemistry, Food, and Health. 5th ed. Cambridge, UK: Thomas Graham House; 1994.
7. Ellis GP The Maillard reaction. Adv Carbohydr Chem 1959; 14: 63-134.
8. Finley JW, Deming DM, Smith RE. Food processing: Nutrition, safety, and quality. In: Shils ME, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 1779.
9. [No author listed.] The chemistry of cooking. LabReporter. Pittsburgh, PA: Fisher Scientific; 2009: No. 3:24.
10. Dudrick SJ, Wilmore DW, Vars HM et al. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery 1968; 64(1): 134-142.
11. Rahbar S. The discovery of glycated hemoglobins: A major event in the study of nonenzymatic chemistry in biological systems. In: Baynes JW, Monnier VM, Ames JM et al, eds. The Maillard reaction: Chemistry at the interface of nutrition, aging, and disease. Ann N Y Acad Sci 2005; 1043: 9-19.
12. Pauling L, Itano HA, Singer SJ et al. Sickle cell anemia, a molecular disease. Science 1949; 109(2835): 543-548.
13. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36(5): 838-843.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329(14): 977-986.
15. Nolte MS, Karam JH. Pancreatic hormones & diabetic drugs. In: Katzung BG, ed. Basic and Clinical Pharmacology. 10th ed. New York, NY: McGraw-Hill; 2007: 693.
16. Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiological Approach. 7th ed. New York, NY: McGraw-Hill; 2008: 1214.
17. Davis SN. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Brunton LL, Parker KL, Murri N et al, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006: 1623-1624.
18. Kroon LA, Assemi M, Carlisle BA. Diabetes mellitus. In: Koda-Kimble MA, Young LY, Alldredge BK et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: 50-14, 50-15.
19. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: What is new and what works. Clin Diabetes 2003; 21: 186-187.
20. Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006; 114(6): 597-605. (Pubitemid 44199649)
21. Baxter JH. Free amino acid stability in reducing sugar systems. J Food Sci 1995; 60(2): 405-408.
22. Krajcovicová-Kudlácková M, Sebeková K, Schinzel R et al. Advanced glycation end products and nutrition. Physiol Res 2002; 51(3): 313-316. (Pubitemid 34970187)
23. Ramasamy R, Vannucci SJ, Yan SS et al. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15(7): 16R-28R.
24. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006; 1(6): 1293-1299.
25. Tan KC, Chow WS, Lam JC et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 2006; 29(3): 329-333. (Pubitemid 44019955)
26. Sparvero LJ, Asafu-Adjei D, Kang R et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 17.
27. Franke S, Sommer M, Rüster C et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 2009; 11(5): R136.
28. Fry LK, Stegink LD. Formation of Maillard reaction products in parenteral alimentation solutions. J Nutr 1982; 112(8): 1631-1637.
29. Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104(8): 1287-1291. (Pubitemid 39036519)
30. Uribarri J, Cai W, Sandu O et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 2043: 461-466. (Pubitemid 41123934)
31. Seiquer I, Díaz-Alguacil J, Delgado-Andrade C et al. Diets rich in Maillard reaction products affect protein digestibility in adolescent males aged 11-14 y. Am J Clin Nutr 2006; 83(5): 1082-1088. (Pubitemid 44713108)
32. Xanthis A, Hatzitolios A, Koliakos G et al. Advanced glycosylation end products and nutrition - a possible relation with diabetic atherosclerosis and how to prevent it. J Food Sci 2007; 72(8): R125-R129.
33. Uribarri J, Woodruff S, Goodman S et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110(6): 911-916.
34. Sandwick R, Johanson M, Breuer E. Maillard reactions of ribose 5-phosphate and amino acids. Ann NY Acad Sci 2005; 1043: 85-96. (Pubitemid 41123893)
35. Murray RK, Granner DK, Mayes PA et al. Harper's Biochemistry. 24th ed. Stamford, CT: Appleton & Lange; 1996: 137-139.
36. Morrison RT, Boyd RN. Organic Chemistry. Boston, MA: Allyn & Bacon; 1959: 628, 629, 746, 766-769.
37. Roberts JD, Caserio MC. Basic Principles of Organic Chemistry. New York, NY: WA Benjamin; 1965: 624, 625.
38. Brady JE, Holum JR. Chemistry: The Study of Matter and Its Changes. 2nd ed. New York, NY: John Wiley & Sons; 1996: 924.
39. Rowlands DA, Wilkinson WR, Yoshimura N. Storage stability of mixed hyperalimentation solutions. Am J Hosp Pharm 1973; 30(5): 436-438.
40. Labuza TP, Massaro SA. Browning and amino acid loss in model total parenteral nutrition solutions. J Food Sci 1990; 55(3): 821-826.
41. Purdue University. Amadori Rearrangement. [Purdue University Website.] Available at: "http://www.cfs.purdue.edu/class/F&N630/amadori- rearrangement.ppt" www.cfs.purdue.edu/class/F&N630/amadori- rearrangement.ppt. Accessed September 2, 2010.
42. The University of Warwick; Warwick Medical School. Food Science and Nutrition and the Maillard Reaction - Melanoidins. [The University of Warwick Website.] June 14, 2007. Available at: "http:// www2.warwick.ac.uk/fac/med/ research/csri/proteindamage/food-nutrition/melanoidins/" www2.warwick.ac.uk/fac/med/research/csri/proteindamage/food-nutrition/ melanoidins/. Accessed September 2, 2010.
43. Smaniotto A Bertazzo A, Comai S, et al. The role of peptides and proteins in melanoidin formation. J Mass Spectrom 2009; 44(3): 410-418.
44. Morales FJ, Babbel MB. Melanoidins exert a weak antiradical activity in watery fluids. J Agric Food Chem 2002; 50(16): 4657-4661.
45. Castello RA, Mattocks AM. Discoloration of tablets containing amines and lactose. J Pharm Sci 1962; 51: 106-108.
46. Klotz R, Sherman JO, Egan T. Preparation of hyperalimentation solutions for the pediatric patient. Am J Hosp Pharm 1971; 28(2): 102-105.
47. Friend JE, Stegink LD, Kann DE. Amino acid stability in aqueous solutions of casein hydrolysate under varied storage conditions. Am J Hosp Pharm 1972; 29(9): 743-748.
48. Kleinman LM, Tangrea JA, Gallelli JF et al. Stability of solutions of essential amino acids. Am J Hosp Pharm 1973; 30(11): 1054-1057.
49. Laegeler WL, Tio JM, Blake MI. Stability of certain amino acids in a parenteral nutrition solution. Am J Hosp Pharm 1974; 31(8): 776-779.
50. Colding H, Andersen GE. Stability of antibiotics and amino acids in two synthetic L-amino acid solutions commonly used for total parenteral nutrition in children. Antimicrob Agents Chemother 1978; 13(4): 555-558. (Pubitemid 8321197)
51. Jurgens RW Jr, Henry RS, Welco A. Amino acid stability in a mixed parenteral nutrition solution. Am J Hosp Pharm 1981; 38(9): 1358-1359.
52. Mirtallo JM, Rogers KR, Johnson JA et al. Stability of amino acids and the availability of acid in total parenteral nutrition solutions containing hydrochloric acid. Am J Hosp Pharm 1981; 38(11): 1729-1731. (Pubitemid 12254151)
53. Nordfjeld K, Rasmussen M, Jensen VG. Storage of mixtures for total parenteral nutrition - long-term stability of a total parenteral nutrition mixture. J Clin Hosp Pharm 1983; 8(3): 265-274. (Pubitemid 13052046)
54. Shine B, Farwell JA. Stability and compatibility in parenteral nutrition solutions. Brit J Parenter Ther 1984; 5(4): 42-50.
55. Parr MD, Bertch KE, Rapp RP. Amino acid stability and microbial growth in total parenteral nutrient solutions. Am J Hosp Pharm 1985; 42(12): 2688-2691. (Pubitemid 16216949)
56. Tripp MG, Menon SK, Mikrut BA. Stability of total nutrient admixtures in a dual-chamber flexible container. Am J Hosp Pharm 1990; 47(11): 2496-2503.
57. Song MK, Lee SW, Suh OK et al. The stability of TPN admixture of amino acids solution and dextrose solution. J Kor Soc Hosp Pharm 1999; 16: 229-240.
58. Newton DW, Driscoll DF. Calcium and phosphates compatibility: Revisited again. Am J Health Syst Pharm 2008; 65(1): 73-80.
59. Blaug SM, Huang WT. Browning of dextrates in solid-solid mixtures containing dextroamphetamine sulfate. J Pharm Sci 1974; 63(9): 1415-1418.
60. Newton DW, Miller KW. Estimating shelf-life of drugs in solution. Am J Hosp Pharm 1987; 44(7): 1633-1640.
61. Newton DW. Three drug stability lives. IJPC 2000; 4(3): 190-193.
62. Wigent RJ. Chemical kinetics. In: Troy DB, ed. Remington: The Science and Practice of Pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 271-272.
63. Allen LV Jr, Popovich NG, Ansel HC. Ansel's Pharmaceutical Dosage Forms and Delivery Systems. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 115, 121.
64. Connors KA, Amidon GL, Kennon L. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists. New York, NY: John Wiley & Sons; 1979: 11, 17-31.
65. Blackburn GL, Bistrian BR, Maini BS et al. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enter Nutr 1977; 1(1): 11-22.
66. Mirtallo J, Canada T, Johnson D et al.; Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe practices for parenteral nutrition. JPEN J Parenter Enter Nutr 2004; 28(6): S39-S70.
67. United States Pharmacopeial Convention, Inc. United States Pharmacopeia 32 - National Formulary 27. Rockville, MD: US Pharmacopeial Convention, Inc.; 2009: 318-354, 1579, 2050, 2107, 3570.
68. McDonald ET. Stability of dextrose solutions of varying pH. J Res Natl Bur Stnds 1950; 45(3): 200-203.
69. Winiarski AP, Infeld MH, Tscherne R et al. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc 2007; 47(6): 747-755.
70. Tamiflu [package insert]. Nutley, NJ: Roche; August 2008.
71. Jacobs J, Nathan I, Superstine E et al. Ampicillin and carbenicillin stability in commonly used infusion solutions. Drug Intell Clin Pharm 1970; 4: 204-208.
72. Savello DR, Shangraw RF. Stability of sodium ampicillin solutions in the frozen and liquid states. Am J Hosp Pharm 1971; 28(10): 754-759.
73. Hiranaka PK, Frazier AG, Gallelli JF. Stability of sodium ampicillin in aqueous solutions. Am J Hosp Pharm 1972; 29(4): 321-322.
74. Hou JP, Poole JW. Kinetics and mechanisms of degradation of ampicillin in solution. J Pharm Sci 1969; 58: 447-454.
75. Finholt P, Jüergensen G, Kristiansen H. Catalytic effect of buffers on degradation of penicillin G in aqueous solution. J Pharm Sci 1965; 54: 387-393.
76. Higgins RH. Letter: Hydroxymethylfuraldimines: Possible intermediates in Maillard reaction. J Pharm Sci 1974; 63(10): 1635-1637.
77. Kirschenbaum HL, Lesko LJ, Mendes RW et al. Stability of procainamide in 0.9% sodium chloride or dextrose 5% in water. Am J Hosp Pharm 1979; 36(11): 1464-1465.
78. Henry DW, Lacerte JA, Klutman NE et al. Irreversibility of procainamide-dextrose complex in plasma in vitro. Am J Hosp Pharm 1991; 48(11): 2426-2429.
79. Gokhale MY, Kirsch LE. Glycosylation of aromatic amines III: Mechanistic implications of the pH-dependent glycosylation of various aromatic amines (kynurenine, 2′-aminoacetophenone, daptomycin, and suflamethoxzaole). J Pharm Sci 2009; 98(12): 4639-4649.
80. Trissel LA. Handbook on Injectable Drugs. 15th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2009: 616.